Quarterly ResultMay 12, 2026, 04:23 PM
iBio Reports Q3 FY26 Results; IBIO-600 Phase 1 Cleared; Pipeline Expanded
AI Summary
iBio, Inc. reported its Q3 fiscal year 2026 financial results, alongside significant corporate advancements. The company received regulatory clearance to initiate its Phase 1 clinical trial for IBIO-600 in Australia, a key step for its obesity therapy. iBio also expanded its pipeline into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) and presented new preclinical data for IBIO-610, showing visceral fat reduction in obese non-human primates. Financially, iBio reported no revenue, an increased net loss of $7.7 million, and ended the quarter with $74.8 million in cash, cash equivalents, and investments.
Key Highlights
- Received regulatory clearance to initiate Phase 1 clinical trial of IBIO-600 in Australia.
- Expanded pipeline into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).
- IBIO-610 preclinical data showed 6.7% visceral fat reduction and 5.2% total fat mass reduction in obese NHPs.
- Reported Q3 FY2026 net loss of $7.73 million, compared to $4.86 million in Q3 FY2025.
- Research and Development expenses increased to $3.3 million from $1.9 million year-over-year.
- General and Administrative expenses rose to $5.1 million from $3.0 million year-over-year.
- Cash, cash equivalents, and investments totaled $74.8 million as of March 31, 2026.
- Received $17 million gross proceeds from warrant exercises in Q4 FY2026, extending cash runway into Q4 FY2028.